David B. Ridley, Professor of the Practice of Business Administration

David Ridley has served as the Faculty Director of the Center for Health Sector Management (HSM) at Duke University's Fuqua School of Business for more than a decade. HSM students comprise nearly 20 percent of Duke MBA graduates each year.

David is an economist focused on incentives for innovation and quality, as well as pricing. He is dedicated to creating and studying tools that improve health.

David was the lead author of two papers that became law. He and his colleagues proposed the Food and Drug Administration's priority review voucher program which became law in 2007. They also proposed the Environmental Protection Agency's vector expedited review voucher program which became law in 2022.

Contact Info:

Office Location:	100 Fuqua Drive, Durham, NC 27708-0120
Email Address:
Web Pages:	https://sites.duke.edu/ridley/ http://www.fuqua.duke.edu/faculty/david-ridley

Teaching (Spring 2024):

• HLTHMGMT 717.401, BIOTECH AND PHARMA STRATEGY Synopsis

  Fuqua GM, MTh 10:30 AM-12:45 PM

• HLTHMGMT 717.402, BIOTECH AND PHARMA STRATEGY Synopsis

  Fuqua GM, MTh 01:45 PM-04:00 PM

• QM 718QH.301, LIFE SCIENCES STRATEGY Synopsis

  TBA, -

Education:

Ph.D.

Duke University

2001

Specialties:

Health Economics
Industrial Organization

Research Interests:

David Ridley is the Dr. and Mrs. Frank A. Riddick Professor of the Practice of Business. He is also the Faculty Director of Duke's Health Sector Management program. In his research, David examines innovation and pricing, especially in health care. He was the lead author of the paper proposing the priority review voucher program The voucher program became law in the U.S. in 2007 and the market price of vouchers has been more than $100 million. David has published in economics journals (American Economic Journal: Economic Policy), medical journals (Journal of the American Medical Association), and scientific journals (Nature Reviews Drug Discovery). David teaches in the daytime MBA and executive MBA programs. He received a PhD in economics from Duke University in 2001.

Areas of Interest:

Health Economics
Industrial Organization
Strategy

Keywords:

Biotechnology • Drug Approval • Drug Costs • Drug Industry • Economics, Pharmaceutical • Elasticity • Health Care Costs • Health Care Economics and Organizations • Health Care Reform • Health Care Sector • Health Policy • Health Services Research • Innovation • Market entry • Patents as Topic • Prescription Fees • Pricing • Product Surveillance, Postmarketing • World Health Organization

Curriculum Vitae

Recent Publications   (More Publications)   (search)

1. Ridley, DB; Lasanta, AM; Storer Jones, F; Ridley, SK, European priority review vouchers for neglected disease product development., BMJ global health, vol. 9 no. 1 (January, 2024), pp. e013686, BMJ [doi]  [abs]
2. Liebman, E; Lawler, EC; Dunn, A; Ridley, DB, Consequences of a shortage and rationing: Evidence from a pediatric vaccine., Journal of health economics, vol. 92 (December, 2023), pp. 102819, Elsevier BV [doi]  [abs]
3. Cuddy, E; Lu, YP; Ridley, DB, FDA Global Drug Inspections: Surveillance Of Manufacturing Establishments Remains Well Below Pre-COVID-19 Levels., Health affairs (Project Hope), vol. 42 no. 12 (December, 2023), pp. 1758-1766 [doi]  [abs]
4. Ridley, DB; Ganapathy, P; Kettler, HE, ​US Tropical Disease Priority Review Vouchers: Lessons In Promoting Drug Development And Access., Health affairs (Project Hope), vol. 40 no. 8 (August, 2021), pp. 1243-1251 [doi]  [abs]
5. Ridley, DB; Lee, CY, Does medicare reimbursement drive up drug launch prices?, Review of Economics and Statistics, vol. 102 no. 5 (December, 2020), pp. 980-993 [doi]  [abs]